GSK-2881078

Among the most clinically advanced SARMs with published Phase II data showing lean mass increases. Still not approved for any indication.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

A Phase II trial in older adults and cancer patients showed modest increases in lean body mass over 12 weeks. HDL suppression was observed dose-dependently. Development status is uncertain.

• Phase II human data showing lean mass gains
• Oral dosing with acceptable short-term tolerability
• Tissue-selective design reducing prostate effects

Phase II studied 1–2 mg/day. No approved therapeutic dose.

• HDL reduction
• Hormonal suppression
• Headache

HDL cholesterol suppression was noted. Not approved for clinical use. Hormonal axis effects expected.

Lean mass gains were statistically significant but clinically modest. Functional improvements were not consistently demonstrated.

• Muscle45
• Recovery30